Clinical Trials Logo

Gastrointestinal Cancer clinical trials

View clinical trials related to Gastrointestinal Cancer.

Filter by:

NCT ID: NCT05837767 Recruiting - Pancreatic Cancer Clinical Trials

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Start date: July 24, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).

NCT ID: NCT05837598 Recruiting - Breast Cancer Clinical Trials

Adapting the Tumor Board Model for Mental Illness and Cancer

Start date: May 31, 2023
Phase: N/A
Study type: Interventional

This study examines the feasibility and acceptability of a virtual tumor board for cancer and mental illness for patients with serious mental illness and a new cancer diagnosis. The study also examines the impact on patient care, psychiatric symptoms, and clinician self-efficacy in managing this population.

NCT ID: NCT05830292 Recruiting - Clinical trials for Gastrointestinal Cancer

Use of DRS Probe and Tracking for In-vivo Application

Start date: May 20, 2022
Phase: N/A
Study type: Interventional

A spectroscopic probe is a sensor designed to illuminate and gather light directly from the tissue while touching it. The probe contains optical fibres, some which illuminate the surface of the tissue with harmless visible (white) light, and others that collects the light that has been reflected from inside the tissue. As the investigators track the position of the probe, they can create spectroscopic images with richer colour information, allowing surgeons to differentiate between different types of tissue, such as normal or cancerous regions. The spectroscopic probe, either sterilised or covered with a sterile probe cover, will be used on the tissue as part of the patient's operation, inside the body itself. The tissue will be sampled using the spectroscopic probe before the surgeons remove the tissue from the body. The research team will be in the operating theatre. The surgeon or a member of the research team will use the optical probe on the tissue samples. This will involve taking pictures and videos of the sample while the research team scan the samples with the spectroscopic probe.

NCT ID: NCT05789485 Recruiting - Clinical trials for Gastrointestinal Cancer

A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers

Start date: April 28, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find the level of aerobic exercise (AT) that is practical, is safe, and has positive effects on the body that may reduce the side effects of therapy. The study will also look at the way the body responds to exercise and whether there are differences in treatment. This will include looking at the highest treatment dose participants receive, how many people stop, delay, or reduce the treatment, and whether additional medication is needed to treat side effects of therapy.

NCT ID: NCT05772546 Recruiting - Clinical trials for Gastrointestinal Cancer

Avatrombopag vs. Placebo for CIT in GI Malignancies

ACT-GI
Start date: November 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: - Avatrombopag (a thrombopoietin receptor agonist) - Matching placebo

NCT ID: NCT05743426 Recruiting - Sarcoma Clinical Trials

Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies

Start date: March 17, 2023
Phase:
Study type: Observational

This prospective, single-institution, observational study explores disease outcomes and toxicities in subjects with gastrointestinal malignancies and sarcoma (bone and soft tissue) who are being treated with standard-of-care therapies including radiotherapy. Recent advances in treatment approaches affected disease outcomes and toxicities. Prospective monitoring of disease outcomes and toxicities using standardized assessments will provide information about recent changes in the standard of care and further refine treatment approaches and prospective clinical trial design.

NCT ID: NCT05694338 Recruiting - Clinical trials for Gastrointestinal Cancer

Frailty in Patients With Gastrointestinal Cancer Who Are Undergoing Major Surgery

Start date: March 13, 2023
Phase:
Study type: Observational

This research is for patients who have gastrointestinal cancer and have a planned major surgery. The purpose of this research is to identify cancer patients who may be at risk for frailty. Frailty is common in older adults and may include symptoms of weight loss, weakness, fatigue, low activity, slow walking and other illnesses. Frailty may increase the risk of problems after major surgery. The study will involve a survey, a blood sample, and a review of medical records.

NCT ID: NCT05664178 Recruiting - Clinical trials for Gastrointestinal Cancer

Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology

Start date: February 20, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to evaluate a tele-resistance training exercise program for individuals undergoing chemotherapy for advanced upper gastrointestinal cancer.

NCT ID: NCT05651672 Recruiting - Clinical trials for Gastrointestinal Cancer

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

Start date: December 2, 2022
Phase: Phase 2
Study type: Interventional

This study is a prospective single-arm phase II study to evaluate the efficacy and safety of Pemigatinib in the advanced gastrointestinal cancer with FGFR 1-3 alterations and failed standard therapy.

NCT ID: NCT05648084 Recruiting - Clinical trials for Gastrointestinal Cancer

Artificial Intelligence and Cancer Staging in Upper Gastrointestinal Malignancies

Start date: December 15, 2022
Phase:
Study type: Observational

Esophageal and stomach cancers, which constitute cancers of the upper region of the digestive system, are cancers that are frequently observed and unfortunately have a low rate of cured patients. In these cases, the stage of cancer at diagnosis is very important for two reasons; First, the stage of the cancer is directly related to the survival time. Secondly, treatment is planned according to the stage. Different treatments are applied to patients at different stages. Currently, the TNM staging (Tumor, Lymph Node and Metastases) system is the accepted one worldwide. Despite many advanced technology tools used in staging (Computed Tomography, Magnetic Resonance Imaging, Endoscopic Ultrasonography), there are still difficulties in correct staging before surgery or before-after neoadjuvant therapy. Artificial intelligence techniques are increasingly used in the field of health, especially in the diagnosis and treatment of cancers. Obtaining cancer details in radiological images, which cannot be noticed by the human eye, by analyzing big data with the help of algorithms gave rise to the application area of "radiomics". It is stated that with Radiomics, there will be improvements in both the diagnosis and staging of cancers and, accordingly, in the treatment. While there are studies on the use of endoscopic methods with artificial intelligence for the early diagnosis of esophageal cancers, a limited number of studies have been conducted on stage estimation from radiological images. In particular, there are not enough studies on the investigation of changes in tumor size after chemotherapy with artificial intelligence and the estimation of staging. In this study, it was aimed to investigate the predictive efficiency of staging and the accuracy of the algorithm developed with artificial intelligence by processing tomography images in a region where esophageal cancers are endemic as a primary outcome and to evaluate the post-treatment mortality, morbidity rates and complication rates of the patients as a secondary outcome.